after joining the study, a complete health evaluation is performed. this includes physical measurements, neurological examinations, and collection of blood samples to establish a starting point for later comparisons.

based on a computer‑generated system, you are assigned to receive either votoplam (the active drug) or a matching placebo tablet. the assignment is concealed from both you and the study team.

you will be given tablets that look identical regardless of assignment. each tablet contains votoplam at a dose of 00 mg (or no active ingredient in the case of the placebo). the tablets are taken by mouth.

the tablets are taken according to the schedule provided by the study staff, typically once each day. the medication is continued for the entire treatment period, which lasts up to 36 months.

throughout the 36‑month period you will attend scheduled visits at the clinic. visits occur at baseline and then approximately every 3 to 6 months (for example, at month 3, month 6, month 12, month 18, month 24, month 30, and month 36). during each visit you will undergo the same assessments performed at baseline, allowing the study to track changes over time.

at every visit you will be asked about any new symptoms or health problems. any adverse events, whether mild or serious, are recorded and reviewed by the study physicians.

at the month 36 visit a comprehensive assessment is performed. the results are compared with the baseline data to determine the effect of votoplam on the progression of huntington’s disease.